SALT LAKE CITY, UT--(Marketwire - June 11, 2008) - Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that the mechanism of action of Flurizan® (tarenflurbil) -- its drug candidate for the treatment of Alzheimer’s disease, is elucidated in the scientific journal Nature. The article, “Substrate-targeting Gamma-secretase Modulators,” will be published in the June 12, 2008 issue of Nature.
